Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Kahwaji

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Permanente Journal|April 27, 2011
How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients?Joseph M Kahwaji, Ryszard R Dudek
Transplantation Proceedings|January 22, 2021
Belatacept Conversion Protocols and Outcomes in Kidney Transplant RecipientsMona Yazdi, Joseph M Kahwaji, Sam Meguerditchian, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 5, 2024
Bisphosphonate Use after Kidney Transplantation Is Associated with Lower Fracture RiskJoseph M Kahwaji, Su-Jau Yang, John J Sim, et al.
Kidney International|January 21, 2017
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodiesMark Haas, James Mirocha, Nancy L Reinsmoen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Permanente Journal|April 27, 2011
How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients?Joseph M Kahwaji, Ryszard R Dudek
Transplantation Proceedings|January 22, 2021
Belatacept Conversion Protocols and Outcomes in Kidney Transplant RecipientsMona Yazdi, Joseph M Kahwaji, Sam Meguerditchian, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 5, 2024
Bisphosphonate Use after Kidney Transplantation Is Associated with Lower Fracture RiskJoseph M Kahwaji, Su-Jau Yang, John J Sim, et al.
Kidney International|January 21, 2017
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodiesMark Haas, James Mirocha, Nancy L Reinsmoen, et al.
Pageof 1